Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

13.6%

3 terminated/withdrawn out of 22 trials

Success Rate

85.0%

-1.5% vs industry average

Late-Stage Pipeline

64%

14 trials in Phase 3/4

Results Transparency

100%

17 of 17 completed trials have results

Key Signals

1 recruiting17 with results

Enrollment Performance

Analytics

Phase 3

13(61.9%)

Phase 2

6(28.6%)

Phase 4

1(4.8%)

Phase 1

1(4.8%)

21Total

Phase 3(13)

Phase 2(6)

Phase 4(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT03720613Recruiting

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Role: lead

NCT05419297Phase 4Unknown

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

Role: collaborator

NCT03006276Phase 3Completed

Efficacy, Tolerability, and Safety Study of DFN-15

Role: lead

NCT03009019Phase 3Completed

Efficacy, Tolerability, and Safety of DFN-15

Role: lead

NCT03996694Phase 1Completed

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

Role: lead

NCT00293033Phase 3Completed

Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

Role: lead

NCT00696137Phase 3Completed

Long-term Extension Study of BEMA™ Fentanyl

Role: lead

NCT01755546Phase 3Completed

Long-term Open-Label Safety Study to Evaluate EN3409

Role: lead

NCT01298765Phase 3Completed

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

Role: lead

NCT02068027Phase 2Completed

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

Role: lead

NCT02643251Phase 2Completed

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

Role: lead

NCT02355158Phase 2Completed

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

Role: lead

NCT01713803Phase 3Withdrawn

Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

Role: lead

NCT02516436Phase 3Withdrawn

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

Role: lead

NCT01666119Phase 2Completed

An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects

Role: lead

NCT01871285Phase 2Completed

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

Role: lead

NCT01633944Phase 3Completed

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

Role: lead

NCT01256450Phase 3Completed

Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain

Role: lead

NCT01675167Phase 3Completed

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

Role: lead

NCT00941304Phase 2Completed

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

Role: lead